Tools
Stock profile

REPLIGEN CORP (RGEN)

RGEN · Latest close $172.67 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$172.67
As of Nov 18, 2026
Tracked funds holding
5 of 149
2026 Q2 13F filings
Opened / added
0 / 4
vs previous quarter
Trimmed / exited
1
vs previous quarter

REPLIGEN CORP (RGEN) is held by 5 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 4 funds adding and 1 fund trimming or exiting versus the previous quarter. Insiders were net sellers over the last 90 days ($0 bought vs $6.0M sold). Latest close $172.67 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Oct 5, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $-6.0M
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Maverick Capital · RTW Investments · Perceptive Advisors — 5 tracked funds hold RGEN. See all holders.

Insider and Congress activity

Insiders bought on the open market (0 purchases, $0) vs 7 sales ($6.0M). Insider trading

Often held alongside

Abivax S.A. (ABVX) · INSMED Inc (INSM) · uniQure N.V. (QURE) · Natera, Inc. (NTRA) · ASML HOLDING NV (ASML) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Maverick Capital2.39%1,984,554ADDED (+30.7%) Q3 filed Nov 16
RTW Investments1.45%1,240,637ADDED (+2.9%) Q3 filed Nov 16
Perceptive Advisors0.51%248,212TRIMMED (-11.5%) Q3 filed Nov 16
Weitz Investment Management0.39%40,800ADDED (+60.0%) Q3 filed Nov 12
Thornburg Investment Management0.06%43,887ADDED (+49.3%) Q3 filed Nov 13

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: +16.7% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

194.5799.202024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding484 of 8,857 filers
Long-only filers among them479
Change vs 2026 Q1+51 net · 456 entered · 405 exited
Shares reported, all filers66,063,132
Reported value, all filers$8.5B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryBiological Products, (No Diagnostic Substances) (SIC 2836)
Revenue · FY2025$738.3M
Net income · FY2025$48.9M
Total assets · FY2025$2.9B
Shares outstanding56,435,621
Market cap (at latest close)$9.7B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 24, 2026.

Short interest

Shares short · Oct 15, 20267,145,036
Share of shares outstanding12.66%
Days to cover4.88

Shares short at recent settlements — Jul 31, 2026: 6.1M · Aug 14, 2026: 6.1M · Aug 31, 2026: 6.6M · Sep 15, 2026: 6.7M · Sep 30, 2026: 7.6M · Oct 15, 2026: 7.1M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 24, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 2K · Sep 30, 2026: 612 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 24, 2026.

Insider trading · Form 4

0 insiders bought on the open market in the last 90 days (0 purchases, $0), against 7 sales by 1 insider ($6.0M).

Source: SEC Form 4 filings. Open-market transactions only.

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Oct 5, 2026Loeillot OlivierChief Executive OfficerSell1,333$178.75$238.3KSEC filing
Oct 5, 2026Loeillot OlivierChief Executive OfficerSell4,202$190.00$798.4KSEC filing
Sep 24, 2026Loeillot OlivierChief Executive OfficerSell8,404$190.00$1.6MSEC filing
Sep 24, 2026Loeillot OlivierChief Executive OfficerSell4,542$190.00$863.0KSEC filing
Sep 21, 2026Loeillot OlivierChief Executive OfficerSell5,426$180.00$976.7KSEC filing
Sep 4, 2026Loeillot OlivierChief Executive OfficerSell3,035$165.90$503.5KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Oct 5, 2026Loeillot OlivierOfficer, Director4,202$798.4KOct 5, 2026SEC filing
Oct 5, 2026Loeillot OlivierOfficer, Director1,333$238.3KOct 5, 2026SEC filing
Sep 24, 2026Loeillot OlivierOfficer, Director12,946$2.5MSep 24, 2026SEC filing
Sep 21, 2026Loeillot OlivierOfficer, Director5,426$976.7KSep 21, 2026SEC filing
Sep 4, 2026Loeillot OlivierOfficer, Director3,035$503.5KSep 4, 2026SEC filing
Aug 20, 2026Loeillot OlivierOfficer, Director5,426$976.7KAug 20, 2026SEC filing
Jul 16, 2026Garland Jason KOfficer530$79.5KJul 16, 2026SEC filing
Jun 25, 2026Garland Jason KOfficer733$106.3KJun 25, 2026SEC filing
Apr 21, 2026Loeillot OlivierOfficer, Director3,832$536.5KApr 21, 2026SEC filing
Dec 17, 2025DAWES KAREN ADirector275$44.3KDec 17, 2025SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 14, 2026T. Rowe Price Associates, Inc.SC 13G/A1,751,8873.1%Jun 30, 2026SEC filing
Jul 31, 2026Vanguard Capital ManagementSC 13G2,825,5795.0%Jun 30, 2026SEC filing
Mar 27, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Feb 17, 2026T. Rowe Price Associates, Inc.SC 13G/A4,599,8608.2%Dec 31, 2025SEC filing
Feb 13, 2026Roy T. Eddleman Living TrustSC 13G/A2,705,6894.8%Dec 31, 2025SEC filing
Feb 5, 2026FMR LLCSC 13G2,891,140.175.1%Dec 31, 2025SEC filing
Sep 8, 2025T. Rowe Price Associates, Inc.SC 13G/A3,429,5476.1%Aug 31, 2025SEC filing
Apr 24, 2025BlackRock, Inc.SC 13G/A5,198,1079.3%Mar 31, 2025SEC filing
Feb 14, 2025T. Rowe Price Associates, Inc.SC 13G/A7,136,08612.7%Dec 31, 2024SEC filing
Feb 13, 2025Roy T. Eddleman Living TrustSC 13G/A2,705,6894.8%Dec 31, 2024SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: no Lobbying Disclosure Act filings matched for this ticker (1999–2026).

Federal contracts: $457.3K in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$-107
FY2022$30.5K
FY2023$0
FY2024$83.2K
FY2025$0
FY2026$343.7K

Largest awards collected

Award IDAgencyAmountStart
75A50121P00074Department of Health and Human Services$14.4MSep 30, 2021
75F40126P00067Department of Health and Human Services$174.6KMay 28, 2026
12639526P0246Department of Agriculture$169.2KAug 29, 2026
HT942524P0046Department of Defense$48.7KFeb 2, 2024
W81XWH20P0093Department of Defense$42.5KMay 21, 2020

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Financial Screens

· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%

· Net-Net (NCAV) — Market cap below net current asset value

Chart Signals

· Monthly Uptrend — Price above its 12-month moving average

· Top Relative Strength — Top 20% of the universe by 6-month return

Red Flags

· Financial Restatement (8-K 4.02) — Last 3 years: a non-reliance / restatement filing (8-K Item 4.02)

· Late Filings (NT) — Last 2 years: a late-filing notification (NT form)

Key figures

· Cash Flow (FCF) — Latest FCF: $93.9M · FCF yield: 880.0% · Positive FCF years: 3

· Net-Net (NCAV) — NCAV: $293.8M · Market cap: $10.7M · NCAV / market cap: 27.54

· Financial Restatement (8-K 4.02) — Latest event: Sep 18, 2024 · Events in 3 yrs: 1

· Late Filings (NT) — Latest event: Mar 3, 2025 · Events in 2 yrs: 2 · Latest form: NT 10-K

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2024 Q2, ranked #18 of 50.

Also held by the tracked funds that hold RGEN — ranked by lift, the co-holding pattern described in Methodology: Abivax S.A. (ABVX) · INSMED Inc (INSM) · uniQure N.V. (QURE) · Natera, Inc. (NTRA) · ASML HOLDING NV (ASML) · CAPITAL ONE FINANCIAL CORP (COF).

Recent 8-K filings

FiledItemsSource
Nov 6, 20261.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation · 3.02 Unregistered Sales of Equity Securities · 9.01 Financial Statements and ExhibitsSEC filing
Oct 30, 20263.02 Unregistered Sales of Equity Securities · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing
Oct 27, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Abivax S.A. (ABVX) · Track Record: how the signals scored · Practice timing on RGEN

One email a week: the week’s new filings and research. Subscribe free

← RGA  ·  RGLD →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.